Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#191 / 200 Total
FMAO - Farmers & Merchants Bancorp Inc - Stock Price Chart
TickerFMAO [NASD, RUT]
CompanyFarmers & Merchants Bancorp Inc
CountryUSA
IndustryBanks - Regional
Market Cap359.55MEPS (ttm)1.99
P/E13.18EPS this Y11.23%
Forward P/E11.61EPS next Y6.78%
PEG-EPS past 5Y2.74%
P/S1.99EPS next 5Y-
P/B1.04EPS Q/Q29.39%
Dividend3.40%Sales Q/Q6.14%
Insider Own8.95%Inst Own26.89%
Insider Trans0.02%Inst Trans-1.75%
Short Float0.70%EarningsApr 28/a
Analyst Recom3.00Target Price26.50
Avg Volume18.00K52W Range20.88 - 34.15
Farmers & Merchants Bancorp, Inc. is a bank holding company, which engages in the provision of commercial banking, retail banking, and financial services. It includes commercial, agricultural, and residential mortgages as well as consumer and credit card lending activities. The firm also offers checking account services, and savings and time deposit services. The company was founded in 1985 and is headquartered in Archbold, OH.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Boyce Ian DDirectorMay 29 '25Buy24.062105,0531,201May 30 10:16 AM
Gerken David RExecutive Vice PresidentSep 10 '24Sale26.4165617,3254,745Oct 21 10:15 AM
STAA - Staar Surgical Co - Stock Price Chart
TickerSTAA [NASD, RUT]
CompanyStaar Surgical Co
CountryUSA
IndustryMedical Instruments & Supplies
Market Cap822.63MEPS (ttm)-1.44
P/E-EPS this Y-552.09%
Forward P/E100.62EPS next Y117.00%
PEG-EPS past 5Y-
P/S2.95EPS next 5Y19.86%
P/B2.35EPS Q/Q-1508.49%
Dividend-Sales Q/Q-44.94%
Insider Own0.52%Inst Own107.96%
Insider Trans-Inst Trans14.21%
Short Float13.30%EarningsMay 07/a
Analyst Recom2.83Target Price18.67
Avg Volume881.52K52W Range13.50 - 49.86
STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The firm offers implantable lenses for the eye and accessory delivery systems. Its products include refractive and cataract solutions through the Collamer brand. The company was founded in 1982 and is headquartered in Lake Forest, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BROADWOOD PARTNERS, L.P.10% OwnerApr 08 '25Buy15.32178,1272,729,09513,510,391Apr 10 07:00 PM
BROADWOOD PARTNERS, L.P.10% OwnerApr 09 '25Buy15.088,200123,67613,518,591Apr 10 07:00 PM
BROADWOOD PARTNERS, L.P.10% OwnerApr 10 '25Buy15.1890013,65813,519,491Apr 10 07:00 PM
BROADWOOD PARTNERS, L.P.10% OwnerApr 04 '25Buy15.91497,6317,917,19113,194,210Apr 07 08:28 PM
BROADWOOD PARTNERS, L.P.10% OwnerApr 03 '25Buy16.97209,5353,555,13812,696,579Apr 07 08:28 PM
NLSP - NLS Pharmaceutics Ltd - Stock Price Chart
TickerNLSP [NASD]
CompanyNLS Pharmaceutics Ltd
CountrySwitzerland
IndustryBiotechnology
Market Cap8.17MEPS (ttm)-2.63
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y33.06%
P/S-EPS next 5Y-
P/B-EPS Q/Q87.78%
Dividend-Sales Q/Q-
Insider Own36.97%Inst Own4.78%
Insider Trans0.00%Inst Trans0.37%
Short Float3.18%Earnings-
Analyst Recom3.00Target Price160.00
Avg Volume289.35K52W Range1.30 - 15.59
NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. Its product portfolio includes Quilience, a treatment for excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol, a treatment for attention deficit hyperactivity disorder. The company was founded by Ronald Hafner, Eric Konofal, and Alexander Zwyer on June 10, 2015 and is headquartered in Zurich, Switzerland.
MLYS - Mineralys Therapeutics Inc - Stock Price Chart
TickerMLYS [NASD, RUT]
CompanyMineralys Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap881.82MEPS (ttm)-3.74
P/E-EPS this Y19.87%
Forward P/E-EPS next Y-0.19%
PEG-EPS past 5Y-170.42%
P/S-EPS next 5Y2.14%
P/B2.57EPS Q/Q-13.15%
Dividend-Sales Q/Q-
Insider Own37.70%Inst Own65.84%
Insider Trans11.89%Inst Trans49.02%
Short Float15.19%EarningsMay 12/a
Analyst Recom1.29Target Price36.00
Avg Volume862.71K52W Range8.24 - 18.38
Jul-01-25 02:42AM Mineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of Lorundrostat (Insider Monkey)
Jun-30-25 11:17AM Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat (GlobeNewswire)
Jun-17-25 07:00AM Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria (GlobeNewswire)
May-27-25 08:10AM Mineralys announces late-breaking presentation of data from Launch-HTN trial (TipRanks)
May-26-25 09:15AM Mineralys reports outcomes from trial of lorundrostat for hypertension (Clinical Trials Arena)
May-24-25 04:30AM Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025) (GlobeNewswire)
May-22-25 08:50AM Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going (Zacks)
May-20-25 08:00AM Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection (GlobeNewswire) +5.09%
May-19-25 12:00PM Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy (Zacks)
May-13-25 07:08AM Q1 2025 Mineralys Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rodman David MalcomChief Medical OfficerJun 12 '25Option Exercise1.086,3486,856113,017Jun 16 04:03 PM
Rodman David MalcomChief Medical OfficerJun 13 '25Sale14.6011,366165,931101,651Jun 16 04:03 PM
Rodman David MalcomOfficerJun 13 '25Proposed Sale14.6011,366165,931Jun 13 04:23 PM
Rodman David MalcomChief Medical OfficerMay 14 '25Sale15.2911,366173,774106,669May 15 07:01 PM
Rodman David MalcomOfficerMay 14 '25Proposed Sale15.2911,366173,774May 14 04:24 PM
GNS - Genius Group Ltd - Stock Price Chart
TickerGNS [AMEX]
CompanyGenius Group Ltd
CountrySingapore
IndustryEducation & Training Services
Market Cap96.52MEPS (ttm)-1.08
P/E-EPS this Y86.41%
Forward P/E-EPS next Y50.00%
PEG-EPS past 5Y-12.86%
P/S12.20EPS next 5Y-
P/B1.17EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own0.80%Inst Own2.34%
Insider Trans0.00%Inst Trans456.25%
Short Float4.38%EarningsApr 30/b
Analyst Recom-Target Price44.59
Avg Volume6.73M52W Range0.21 - 2.85
Genius Group Ltd. engages in developing artificial intelligence education. It offers educational, entrepreneurship, business, psychometric tests, and entrepreneur education platform. Its brands include GeniusGroup, geniusU, openexo, Education Angels, E-Square Education, pin, FatBrAin, and Revealed Films. It operates through the Education and Campus segments. The Education segment refers to entrepreneur education, management, and business development tools. The Campus segment includes resorts, retreats, and co-working cafes for entrepreneurs. The company was founded by Roger James Hamilton on November 30, 2015 and is headquartered in Singapore.
CHGG - Chegg Inc - Stock Price Chart
TickerCHGG [NYSE]
CompanyChegg Inc
CountryUSA
IndustryEducation & Training Services
Market Cap142.80MEPS (ttm)-8.29
P/E-EPS this Y-78.67%
Forward P/E11.36EPS next Y-26.29%
PEG-EPS past 5Y-151.46%
P/S0.25EPS next 5Y-
P/B0.76EPS Q/Q-1096.40%
Dividend-Sales Q/Q-30.38%
Insider Own7.19%Inst Own63.10%
Insider Trans-0.36%Inst Trans-16.84%
Short Float7.86%EarningsMay 12/b
Analyst Recom3.67Target Price1.00
Avg Volume3.71M52W Range0.44 - 3.81
Chegg, Inc. engages in providing support and a learning platform for students. Its services include Chegg Study Pack, Chegg Study, Chegg Writing, Chegg Math, Busuu offerings, Chegg Skills, advertising services, print textbooks, and eTextbooks offerings. It operates through the United States and International geographical segments. The company was founded by Osman Rashid and Aayush Phumbhra on July 29, 2005 and is headquartered in Santa Clara, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BUDIG RENEE VARNIDirectorJun 06 '25Sale1.4127,97339,55485,742Jun 10 02:53 PM
RENEE BUDIGDirectorJun 06 '25Proposed Sale1.4127,97339,559Jun 06 04:06 PM
ALT - Altimmune Inc - Stock Price Chart
TickerALT [NASD, RUT]
CompanyAltimmune Inc
CountryUSA
IndustryBiotechnology
Market Cap359.30MEPS (ttm)-1.25
P/E-EPS this Y5.69%
Forward P/E-EPS next Y-24.49%
PEG-EPS past 5Y3.48%
P/S17965.23EPS next 5Y0.61%
P/B2.43EPS Q/Q24.79%
Dividend-Sales Q/Q0.00%
Insider Own1.04%Inst Own47.37%
Insider Trans1.32%Inst Trans-5.65%
Short Float30.40%EarningsMay 13/b
Analyst Recom1.22Target Price22.38
Avg Volume5.23M52W Range2.90 - 11.16
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sohn Catherine A.DirectorMar 17 '25Buy5.781,0005,7841,000Mar 18 04:15 PM
WEAVER GREGORY LChief Financial OfficerMar 13 '25Buy5.2010,00051,99610,000Mar 14 07:27 AM
Garg Vipin KPresident and CEOJan 30 '25Option Exercise0.0026,7750342,696Feb 03 08:50 PM
Garg Vipin KPresident and CEOFeb 01 '25Option Exercise0.0016,5450351,645Feb 03 08:50 PM
Garg Vipin KPresident and CEOFeb 02 '25Option Exercise0.0018,9500363,364Feb 03 08:50 PM
INR - Infinity Natural Resources Inc - Stock Price Chart
TickerINR [NYSE, RUT]
CompanyInfinity Natural Resources Inc
CountryUSA
IndustryOil & Gas E&P
Market Cap911.32MEPS (ttm)-
P/E-EPS this Y13.68%
Forward P/E4.37EPS next Y61.71%
PEG-EPS past 5Y-
P/S-EPS next 5Y22.56%
P/B-EPS Q/Q-748.43%
Dividend-Sales Q/Q198.00%
Insider Own76.37%Inst Own24.28%
Insider Trans0.17%Inst Trans41.22%
Short Float3.08%EarningsMay 12/a
Analyst Recom1.12Target Price26.12
Avg Volume286.63K52W Range13.64 - 23.00
Infinity Natural Resources, Inc. is a holding company, which engages in the acquisition, development, and production of hydrocarbons in the Appalachian Basin. It focuses on the volatile oil window of the Utica Shale in eastern Ohio. The company was founded by Ryan Warner on June 6, 2017 and is headquartered in Morgantown, WV.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
James SarahDirectorJun 25 '25Sale18.402,50046,0040Jul 07 09:42 PM
GRAY STEVEN DDirectorFeb 03 '25Buy20.0015,000300,00015,000Feb 03 06:13 PM
Poole David PDirectorFeb 03 '25Buy20.0012,500250,00012,500Feb 03 06:08 PM
Gieselman ScottDirectorFeb 03 '25Buy20.0050,0001,000,00050,000Feb 03 06:06 PM
James SarahDirectorFeb 03 '25Buy20.002,50050,0002,500Feb 03 05:55 PM
ABSI - Absci Corp - Stock Price Chart
TickerABSI [NASD, RUT]
CompanyAbsci Corp
CountryUSA
IndustryBiotechnology
Market Cap329.10MEPS (ttm)-0.93
P/E-EPS this Y7.58%
Forward P/E-EPS next Y11.17%
PEG-EPS past 5Y-29.30%
P/S68.28EPS next 5Y3.62%
P/B1.66EPS Q/Q4.25%
Dividend-Sales Q/Q31.29%
Insider Own12.61%Inst Own65.99%
Insider Trans0.00%Inst Trans14.83%
Short Float23.41%EarningsMay 13/a
Analyst Recom1.00Target Price9.12
Avg Volume3.19M52W Range2.01 - 6.33
Jul-03-25Resumed Morgan Stanley Overweight $7
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.
CDXS - Codexis Inc - Stock Price Chart
TickerCDXS [NASD, RUT]
CompanyCodexis Inc
CountryUSA
IndustryBiotechnology
Market Cap213.74MEPS (ttm)-0.99
P/E-EPS this Y22.15%
Forward P/E-EPS next Y17.01%
PEG-EPS past 5Y-33.31%
P/S4.29EPS next 5Y41.30%
P/B4.31EPS Q/Q-52.40%
Dividend-Sales Q/Q-55.82%
Insider Own3.23%Inst Own83.26%
Insider Trans140.25%Inst Trans7.29%
Short Float7.93%EarningsMay 14/a
Analyst Recom1.57Target Price7.08
Avg Volume851.34K52W Range1.90 - 6.08
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Opaleye Management Inc.10% OwnerJun 27 '25Buy2.39100,000239,00012,350,000Jul 01 04:05 PM
Opaleye Management Inc.10% OwnerJun 12 '25Buy2.25100,000225,00012,100,000Jun 16 04:59 PM
Opaleye Management Inc.10% OwnerJun 13 '25Buy2.2399,102220,99712,199,102Jun 16 04:59 PM
Opaleye Management Inc.10% OwnerJun 16 '25Buy2.2450,898114,01212,250,000Jun 16 04:59 PM
Opaleye Management Inc.10% OwnerMay 23 '25Buy2.362,320,0005,475,20011,995,000May 28 04:05 PM
110151617181920